Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)
| Autor: | Mary Louise Keohan, Linda S. Ahn, Cristina R. Antonescu, Murray F. Brennan, Robert G. Maki, David R. D'Adamo, Samuel Singer, Veridiana Pires de Camargo |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment Antineoplastic Agents Systemic therapy Article Recurrence Internal medicine medicine Humans Aged Chemotherapy business.industry Fibromatosis Middle Aged medicine.disease Primary tumor Surgery Radiography Fibromatosis Aggressive Treatment Outcome Response Evaluation Criteria in Solid Tumors Disease Progression Hormonal therapy Female Hormone therapy business Progressive disease |
| Zdroj: | Cancer. |
| ISSN: | 1097-0142 0008-543X |
| Popis: | BACKGROUND: In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to provide a basis for the examination of newer agents. METHODS: Records of patients with desmoid tumors who were treated with chemotherapy at the study institution were reviewed. The activity of nonsteroidal anti-inflammatory drugs was not addressed. Patients without measurable disease and those receiving therapy could not be documented, and those receiving prophylactic therapy were excluded. RESULTS: A total of 68 patients received 157 lines of therapy. At the time of last follow-up, 9 patients had died, 7 of progressive disease. The cohort was 62% female, with a median age of 32.5 years. Approximately 32% of the patients had Gardner syndrome. The median follow-up was 63 months, and patients received a median of 2 lines of therapy. An intra-abdominal primary tumor location was the most common (44%). The greatest Response Evaluation Criteria in Solid Tumors (RECIST) response rate was observed with anthracyclines and hormonal therapy and the lowest response was noted with single-agent dacarbazine/temozolomide or tyrosine kinase inhibitors, principally imatinib. On multivariate analysis, macroscopic nodular morphology and the presence of Gardner syndrome were the only tumor factors found to be associated with a greater time to disease progression. CONCLUSIONS: Compared with other agents, antiestrogens and anthracycline-containing regimens appear to be associated with a higher radiological response rate against desmoid tumors. Systemic therapy can be successful in patients with desmoid tumors, and is a viable option in lieu of morbid or disabling surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text